Page last updated: 2024-09-03

phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Mononeuropathies

phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with Mononeuropathies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bajpai, A; Bertozzi, F; Gardell, LR; Gaubert, G; Jacobi, PM; Kelly, N; Lameh, J; Nguyen, D; Olsson, R1

Other Studies

1 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Mononeuropathies

ArticleYear
Neuropeptide FF receptors have opposing modulatory effects on nociception.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 334, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclic AMP; Disease Models, Animal; Hyperalgesia; Ligands; Male; Mice; Mononeuropathies; NIH 3T3 Cells; Oligopeptides; Pain Measurement; Pain Threshold; Rats; Receptors, Neuropeptide; Small Molecule Libraries; Transfection

2010